MondayNightIBD ~ Treat-to-Target Clinical Convo
October 21, 2024 ~ Jami Kinnucan, MD
***Post-Survey & Application for CME Credit***

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.
1.What are your specialty & credentials?(Required.)
2.What is your community of practice?
3.In the CALM study comparing conventional treatment vs T2T treatment escalation in bionaive Crohn's patients starting adalimumab, mucosal healing at week 48 was defined as?

(CDEIS: Crohn's Disease Endoscopic Index of Severity)
(Required.)
4.55 with recent diagnosis of colonic Crohn’s disease, SESCD 6, FCP 850, started on Vedolizumab. At 3 month FCP 100, Colonoscopy at 1yr : endo remission.

According to the AGA 2023 guidelines, how can you periodically (every few months) rule out active inflammation moving forward?
(Required.)
EVALUATION FORM
5.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
Utilize best practices and data supporting treat-to-target approach for optimized care of patients with Crohn’s disease
6.Please indicate the extent of your agreement with the following statements:
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective
7.Overall, was this activity fair, balanced and free from commercial bias?
8.If no, please explain:
9.Of the patients with IBD you will see in the next month, about how many will benefit from the information you learned today?
10.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
11.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
12.For purposes of certification, you must complete the following information.
*Please note that we will not forward or sell your contact information.*
(Required.)
13.I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | Treat-to-Target" and claim 1.0 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com
Privacy & Cookie Notice